Study population | Medications | Person-years | No. of HF events | Crude incidence (per 1000 person-years) | Adjusted HR of HF (95% CI) | |
---|---|---|---|---|---|---|
Primary diagnosis only | DPP-4 inhibitors | 77,070 | 3107 | 40 | 0.84 (0.80, 0.89) | |
GLP-1 agonists | 70,706 | 3424 | 48 | Reference | ||
Extend follow-up to 45 days | DPP-4 inhibitors | 94,201 | 5714 | 61 | 0.89 (0.85, 0.92) | |
GLP-1 agonists | 89,315 | 6098 | 68 | Reference |